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1Chapter
Treatment of Children with 
Osteosarcoma
Maxim Yu. Rykov and Elmira R. Sengapova
Abstract
Osteosarcoma accounts for 3% of all malignant tumors, 35–50% of all  
malignant bone tumors in pediatric patients. The chapter contains statistical data 
describing the incidence of the child population of osteosarcomas, classification 
of osteosarcomas, staging principles, a description of the main localizations, as 
well as a detailed description of the existing treatment protocols for children 
with osteosarcomas, including personalized therapy. The literature data are 
described in detail—the results of treatment of children with osteosarcoma 
with various courses of chemotherapy, as well as new approaches in treatment, 
including personalized therapy. But the results of treatment of children with 
primary metastatic osteosarcoma, relapse, and refractory course of the disease 
remain unsatisfactory.
Keywords: pediatric oncology, osteosarcoma, chemotherapy, personalized therapy, 
combination treatment
1. Introduction
Osteosarcoma is a primary malignant bone tumor that develops from primitive 
mesenchymal stem cells capable of differentiating into bone, cartilage, or fibrous 
tissue [1].
Osteosarcoma accounts for 3% of all malignant tumors, 35–50% of all malignant 
bone tumors in pediatric patients. The frequency of occurrence is 4 cases per 1 mil-
lion children and adolescents per year. About 60% of cases of osteosarcoma detec-
tion are recorded at the age of 10–20 years (mainly in the prepubertal and pubertal 
periods). The gender ratio (boys/girls) is 1.3–1.6:1 [2].In 50% of cases, the tumor is 
located in the projection of the knee joint (distal femur, proximal tibial bone). The 
third place in terms of frequency of occurrence is the lesion of the proximal meta-
diaphysis of the humerus. The defeat of the axial skeleton (pelvis, spinal column) is 
detected in 12% of cases [3–5].
In the treatment of children with osteosarcoma, chemotherapy is the main 
method. Nonadjuvant and adjuvant chemotherapy courses are important. In the 
middle of the twentieth century, when the main treatment was surgical, the fre-
quency of relapse and metastasis was extremely high. Increased patient survival 
is due precisely to the intensification of chemotherapeutic treatment, which has 
reduced the frequency of relapses and metastasis.
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2. Classification and staging
2.1  WHO classification of soft tissue and bone tumors of 2013  
(fourth revision)
A localized (locally advanced) variant of osteosarcoma, which occurs in 80% 
of cases and a disseminated (primary metastatic) variant, which occurs in 20% of 
cases, are distinguished [3, 6].
2.2 Histological classification
• low grade, central osteosarcoma
• classic (conventional) version of osteosarcoma:
 ○ chondroblastic osteosarcoma
 ○ fibroblastic osteosarcoma
 ○ osteoblastic osteosarcoma
 ○ osteosarcoma, unspecified accuracy
• telangiectatic osteosarcoma
• small cell osteosarcoma
• high degree of malignancy, superficial osteosarcoma.
2.3 TNM classification 2018:
2.3.1 TNM classification 2018 for the extremities
T—primary tumor
Tx—the primary tumor cannot be determined [7].
T0—no signs of primary tumor.
T1—the largest tumor size ≤8 cm.
T2—the largest tumor size>8 cm.
T3—several unrelated tumors in the primary zone of bone damage.
N—regional lymph nodes:
Nx—the presence of metastatic lesions in the regional lymph nodes cannot be 
determined.
N0—no regional metastases in the lymph nodes.
N1—regional lymph node metastases.
M—distant metastases:
Mx—the presence of distant metastases could not be determined or the study 
was not conducted.
M0—distant metastases are absent.
M1—there are distant metastases.
M1a—in the lungs.
M1b—another localization.
G—degree of differentiation:
Gx—the degree of differentiation could not be determined or the study was not 
conducted.
3Treatment of Children with Osteosarcoma
DOI: http://dx.doi.org/10.5772/intechopen.83756
G1—well differentiated.
G2—moderately differentiated.
G3—poorly differentiated.
G4—undifferentiated.
G1–2—low degree of malignancy.
G3–4—a high degree of malignancy.
2.3.2 TNM classification 2018 for the spine
2.3.3 TNM classification 2018 for the pelvis
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor confined to one vertebral segment or two adjacent vertebral segments
T2 Tumor confined to three adjacent vertebral segments
T3 Tumor confined to four or more adjacent vertebral segments, or any nonadjacent vertebral segments
T4 Extension into the spinal canal or great vessels
T4a Extension into the spinal canal
T4b Evidence of gross vascular invasion or tumor thrombus in the great vessels
NX Regional lymph nodes cannot be assessed.
Because of the rarity of lymph node involvement in bone sarcomas, the designation NX may not be 
appropriate, and cases should be considered N0 unless clinical node involvement clearly is evident
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
cM0 No distant metastasis
cM1 Distant metastasis
cM1a Lung
cM1b Bone or other distant sites
pM1 Distant metastasis, microscopically confirmed
cM1a Lung, microscopically confirmed
cM1b Bone or other distant sites. Microscopically confirmed
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor confined to one pelvic segment with no extraosseous extension
T1a Tumor ≤8 cm in greatest dimension
T1b Tumor >8 cm in greatest dimension
T2 Tumor confined to one pelvic segment with extraosseous extension or two segments without 
extraosseous extension
T2a Tumor ≤8 cm in greatest dimension
T2b Tumor >8 cm in greatest dimension
T3 Tumor spanning two pelvic segments with extraosseous extension
T3a Tumor ≤8 cm in greatest dimension
T3b Tumor >8 cm in greatest dimension
Osteosarcoma – Diagnosis, Mechanisms, and Translational Developments
4
Staging according to the TNM classification is presented in Table 1.
3. Treatment
The methods of treatment of osteosarcoma over the past 30 years have not 
changed. There are five main drugs (cisplatin, adriamycin, methotrexate, ifos-
famide, and etoposide) that have been used in various combinations and doses 
[8–13].
The rates of treatment outcome in the world remain at about the same level. In 
patients with a localized variant of osteosarcoma, 5-year overall survival (OS) does 
not exceed 75% and 5-year event-free survival (EFS)—62% (Table 2).
In patients with primary metastatic osteosarcoma, the results are much 
worse, despite attempts to use high doses of drugs, including high-dose poly-
chemotherapy with transplantation of autologous hematopoietic stem cells. At 
the same time, the 5-year OS does not exceed 35% on average and the 5-year 
EFS–25% (Table 2).
Stage TNM Degree of malignancy
IA T1 N0 M0 Low
IB T2 N0 M0 Low
IIA T1 N0 M0 High
IIB T2 N0 M0 High
III T3 N0 M0 Any
IVA Any Т N0 M1a Any
IVB Any Т N1 Any М
Any Т Any N М1b
Any
Any
Table 1. 
Staging by TNM.
T4 Tumor spanning three pelvic segments or crossing the sacroiliac joint
T4a Tumor involves sacroiliac joint and extends medial to the sacral neuroforamen
T4b Tumor encasement of external iliac vessels or presence of gross tumor thrombus in major pelvic 
vessels
NX Regional lymph nodes cannot be assessed.
Because of the rarity of lymph node involvement in bone sarcomas, the designation NX may not be 
appropriate, and cases should be considered N0 unless clinical node involvement clearly is evident
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
cM0 No distant metastasis
cM1 Distant metastasis
cM1a Lung
cM1b Bone or other distant sites
pM1 Distant metastasis, microscopically confirmed
cM1a Lung, microscopically confirmed
cM1b Bone or other distant sites. Microscopically confirmed
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3.1 Traditional treatment
The most significant interest in the treatment of children with a localized version 
of osteosarcoma are the studies of the Italian and Scandinavian groups (Italian and 
Scandinavian sarcoma group–ISG/SSGI, SSG XIV), the French Pediatric Oncological 
Group (Societe Francaise d’Oncologie Pediatrique–SFOP OS94), and EURAMOS1.
Ferrari et al. showed the data of the joint study of the Italian and Scandinavian 
groups (ISG/SSG I), which was conducted from 1997 to 2000. The study included 
182 patients.
A special feature of neoadjuvant chemotherapy was the use of two courses 
of monotherapy with high-dose ifosfamide (in a course dose of 15 g/m2) and 
two courses of MAR (methotrexate (M) 12 g/m2, adriamycin (A) 75 mg/m2, and 
cisplatin (P) 120 mg/m2) in alternating mode. Adjuvant chemotherapy started at 
week 14. In this case, the course dose of adriamycin was increased to 90 mg/m2, the 
dose of cisplatin to 150 mg/m2, and a high-dose ifosfamide was administered in PIM 
chemotherapy courses (cisplatin, ifosfamide, and methotrexate) and PAI (cisplatin, 
adriamycin, and ifosfamide).
After removal of the primary tumor focus, a good histological response (thera-
peutic pathomorphism of grade 3–4) was achieved in 63% of patients, a poor histo-
logical response (treatment pathomorphism of grade 1–2) in 37%. At the same time, 
the 5-year OV and EFS accounted for 77 and 64%. Consequently, the use of high-
dose ifosfamide in an alternating mode with the MAP scheme led to an increase in 
the frequency of achieving a good histological response, but did not affect the rates 
of OS and EFS [15, 16, 31].
Smeland et al. presented the data of the study of the Scandinavian Group (SSG 
XIV), which was conducted from 2001 to 2005. The study included 63 patients.
Therapy program 5-year overall 
survival, %
5-year 
event-free 
survival, %
IOR/OS2 the Istituto Ortopedico Rizzoli [14] 75 63
ISG/OS1 (Italian Sarcoma Group) [15] 74 64
ISG/SSG1 (Italian and Scandinavian Sarcoma Group) [16] 77 64
COSS 88/96 (Cooperative Osteosarcoma Study Group) [17] 79
SSG XIV (Scandinavian Sarcoma Group) [18] 65
NECO93J/95J (Neoadjuvant Chemotherapy for Osteosarcoma) [19] 78 65
BOTG III/IV (Brazilian Osteosarcoma Treatment Group) [20] 61 45
POG8651 (Pediatric Oncology Group) [21] 78 65
SFOP94 (Société Française d’Oncologie Pédiatrique) [22] 76 62
St.Jude CRH OS91 (Children Research Hospital) [23] 74 65
St.Jude CRH OS99 (Children Research Hospital) [24] 79 67
INT0133-COG (+MTP/-MTP) Children’s Oncology Group [25] 78/70 67/61
MSKC NY (+PAM) Memorial Sloan-Kettering Cancer Center, NY [26] 94 72
COG INT0133, CCG7943, AOST0121 [27] 47 22
ISG/SSG II (Italian and Scandinavian Sarcoma Group) [28] 55 46
EURAMOS1 [29, 30] 75 59
Table 2. 
The results of the treatment of pediatric patients with localized osteosarcoma.
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Neoadjuvant chemotherapy consisted of two courses of IDA. High-dose ifos-
famide (in the course dose of 10 g/m2) was used in monotherapy in patients with a 
poor histological response to treatment, only after five courses of MAP.
After removal of the primary tumor lesion, a good histological response was 
achieved in 45% of patients and a poor histological response in 55%. At the same 
time, the 5-year OV and BSV accounted for 76–65% and the 5-year EFS in the 
group with a good histological response for 89%, with a poor histological response 
48%. Consequently, the use of ifosfamide after MAP courses in the adjuvant mode 
did not lead to an increase in OS and EFS, and the frequency of achieving a good 
histological response was lower than in studies in which the MAP scheme was used 
in alternating mode with ifosfamide [18].
Le Deley et al. presented the results of the randomized SFOP OS94 study, which 
was conducted from 1994 to 2001. The study included 239 patients (120 in group A 
and 119 in group B).
Neoadjuvant therapy included seven courses of high-dose methotrexate and two 
courses of monotherapy with adriamycin (in a course dose of 70 mg/m2) in group 
A or seven courses of high-dose methotrexate and two courses of IE (ifosfamide (I) 
12 g/m2 and etoposide (E) 300 mg/m2) in group B. In the adjuvant mode, chemo-
therapy was replaced with IE courses in group A, and AP in group B for patients 
with a poor histological response detected after removal of the primary focus. The 
operative stage of treatment was carried out at 12 and 14 weeks in groups A and B, 
respectively.
A good histological response was achieved in group A in 43% of patients, in 
group B in 64%, poor histological response in group A in 57%, and in group B in 
36% (p = 0.009). The 5-year OS in group A was 75%, in group B—76%, the 5-year 
EFS in group A—58%, and in group B—66%. A 3-year EFS in group A in patients 
showed a good histological response for 82%, with a poor histological response for 
49%, in group B—77 and 60%, respectively.
Consequently, the use of methotrexate, ifosfamide and etoposide in neoadjuvant 
chemotherapy led to a statistically significant increase in the frequency of achieving 
a good histological response, but not to an increase in OS and EFS [22].
Of particular interest in the treatment of children with primary metastatic 
osteosarcoma are the Pediatric Oncology Group (POG) IE and ISG/SSG II 
studies.
Goorin et al. presented the results of a phase II/III nonrandomized clinical trial 
of high-dose ifosfamide and etoposide in patients with primary metastatic osteosar-
coma. The study included 43 patients.
Neoadjuvant chemotherapy was represented by two courses of IE (ifosfamide 
(I) 17.5 g/m2 and etoposide (E) 500 mg/m2). Removal of the primary tumor lesion 
was performed after two courses of IE at 7–8 weeks of therapy. The timing of the 
removal of metastatic foci was chosen individually during adjuvant chemotherapy, 
which included four courses of MAP chemotherapy and three courses of iE (with a 
course dose of ifosfamide (i) 12 g/m2) in an alternating mode.
A good histological response was achieved in 65% of patients and poor in 35%. 
However, the 2-year OS and EFS were 55 and 45%, respectively. Consequently, 
the use of high-dose ifosfamide in combination with etoposide therapy led to an 
increase in the frequency of achieving a good histological response, but not indica-
tors of OS and EFS [32].
Boye et al. showed the results of the nonrandomized study ISG/SSG II, which 
was conducted from 1996 to 2004. The study included 57 patients with primary 
metastatic osteosarcoma.
Neoadjuvant chemotherapy included two courses of MAPI. Surgical removal of 
the primary tumor lesion was performed at week 14.
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In the adjuvant mode, two courses of ACyVP (adriamycin (A) 90 mg/m2, 
cyclophosphamide (Cy) 4 g/m2, and vepesid (VP) 600 mg/m2) and two courses 
of high-dose chemotherapy VPCarbo (vepesid (VP) 600 mg/m2 and carboplatin 
(Carbo) 1.5 g/m2) with the support of autologous hematopoietic stem cells. Surgical 
removal of the primary tumor lesion was performed at week 14.
A good histological response was achieved in 29% of patients and poor in 71%. 
The 5-year OM and BSV were 31 and 27%, respectively [28].
Marina et al. presented the results of the EURAMOS1 study in patients with 
a poor histological response after neoadjuvant MAP chemotherapy. Within the 
protocol, patients are randomly assigned to the MAP treatment lines (methotrexate 
(M) 12 g/m2, adriamycin (A) 75 mg/m2, and cisplatin (P) 120 mg/m2) and MAPIE 
(ifosfamide (I) 14 g/m2 and etoposide 500 mg/m2). In the age group up to 30 years, 
the MAPIE line of therapy was carried out in 310 patients, the MAPIE line in 308 
patients, in the age group up to 20 years—259 (84%) and 271 (88%) patients. 
Groups of patients are statistically significantly comparable by sex, age, localization 
of the primary tumor lesion, the presence of metastatic lesions, and the histological 
variant of the tumor.
In the group of 541 patients with a localized version of osteosarcoma, 247 events 
were identified, 118 in patients who received the MAP therapy line and 129 in 
patients who received the MAPIE therapy line. At the same time, the 3-year EFS was 
60 and 57%. In the group of patients with primary metastatic osteosarcoma, 3-year 
EFS was 24 and 18%, for MAP and MAPIE, respectively. Therefore, this study 
showed that the use of alternating chemotherapy courses for MAP, IE, and Ai in an 
adjuvant regimen did not lead to an increase in EFS indices [33].
3.2 Experimental treatment
Treatment outcomes for children with primary metastatic osteosarcoma remain 
extremely low and the optimal therapeutic strategy is unknown.
New programs are being developed around the world taking into account the 
molecular biological features of tumor cells that determine sensitivity to chemo-
therapy (ERCC1 to cisplatin, TOPO2α to anthracyclines and etoposide, MGMT 
to epigenetic therapy and cisplatin, RFC1 to methotrexate) [34–39] and invasive 
and metastatic potential of a tumor (stem cell markers—CD133, OCT4; transcrip-
tion factors—p-STAT3, C-MYC; cytokine-associated signaling pathways—ErbB2, 
VEGFR1, VEGFR2, PDGFRα, and PDGFRβ) [40–43].
Cui et al. presented the results of a study to determine the expression of MGMT 
protein (methylguanine–DNA–methyltransferase) and MGMT gene methylation 
in patients with osteosarcoma in the age group up to 40 years (mean age 17 years) 
who were treated with cisplatin in single mode, in a course dose of 120 mg/m2 
Determination of MGMT protein expression in immunohistochemical (IHC) study 
was performed in biopsy tumor material in 76 patients and MGMT gene methyla-
tion in 51 patients. The result of IHC was considered positive with a high level of 
expression—more than 30% (3+), with an average level of expression—20–30% 
(2+), and with a low level of expression—10–20% (1+). MGMT protein expression 
was detected in 52 (68%) patients, low expression level in 27 (35%), medium level 
in 18 (24%), and high level in 7 (9%).
A statistically significant relationship was established between the presence of 
MGMT protein expression and an increase in the frequency of a poor histological 
response (p = 0.004). The expression level above 20% was detected in 22 out of 
43 (51%) patients in the group of patients with 1–2°of therapeutic pathomorpho-
sis and only in 3 out of 33 (9%) patients in the group with 3–4° of therapeutic 
pathomorphosis.
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Methylation of the promoter portion of the MGMT gene was observed in 12 of 
51 (23.5%) patients and the lack of expression of MGMT protein in 14 of 51 (27.5%) 
patients. A statistically significant relationship between the absence of methylation 
and the presence of MGMT protein expression (p < 0.001) was established. In the 
group of patients with 1–2 degrees of therapeutic pathomorphosis, the absence of 
MGMT gene methylation was detected in 36 of 38 (94.7%) patients and with 3–4 
degrees of therapeutic pathomorphosis in 3 of 13 (23%) patients (p < 0.001).
Consequently, the data obtained indicate the formation of tumor resistance to 
treatment with an alkylating agent—cisplatin in patients whose biopsy material 
revealed the absence of methylation of the promoter portion of the MGMT gene 
and the presence of expression of the MGMT protein [34, 35].
Pitano-Garcia et al. (Spain sarcoma group) conducted a study to determine the 
expression of RFC1 micro-RNA (reduced folate carrier 1, a transmembrane protein 
that provides folate and methotrexate transport to the cell) by real-time polymerase 
chain reaction (PCR) in a tumor substrate in children with osteosarcoma.
In 34 samples, biopsy tumor material in 14 children and metastatic foci tumor 
material in 20 children were analyzed. In 13 of 14 (92.9%) biopsy specimens and 
in 11 of 20 (68.8%) metastatic specimens, a low level of RFC1 expression was 
detected.
A poor histological response after neoadjuvant chemotherapy (three  
courses of intravenous administration of doxorubicin at a dose of 75 mg/m2, 
three courses of intraarterial administration of cisplatin at a dose of 105 mg/m2, 
four courses of intravenous administration of methotrexate at a dose of 14 g/m2)  
in 45% of cases. The biopsy tumor substrate in this group of patients was 
characterized by a low level of expression of RFC1 micro-RNA in 90% of cases 
compared to 60% in patients with a good histological response (p = 0.053). The 
average level of expression was statistically significantly lower in the biopsy 
material than in the metastatic tumor foci (p = 0.024) [38, 44].
Therefore, in this study, there was a tendency to an increase in the frequency 
of detection of low expression levels of RFC1 micro-RNA in patients with a poor 
histological response.
Hattinger et al. (Italian sarcoma group) presented the results of the study, the 
purpose of which was to determine the prognostic significance of ERCC1 protein 
expression (excision repair crosscomplementation group 1) in biopsy tumor mate-
rial in patients with localized osteosarcoma, who underwent programmed treat-
ment of ISG/OS-oss and ISG/SSG1. A tumor sample was considered positive in the 
presence of a score of 2–3: score 1 (1–10% of positive nuclei), score 2 (11–50% of 
positive nuclei), and score 3 (more than 50% of positive nuclei).
ERCC1-positive tumor (score 2–3) was detected in 30 patients (30%). During 
the ISG/OS-oss program in groups of patients with ERCC1-negative/score 1 and 
ERCC1-positive (score 2–3), the 5-year-old OS and BSV tumor variants were 91, 
38, and 57, 25% (p = 0.001; p = 0.042), with the ISG/SSG1 program–82, 64, and 69, 
36% (p = 0.022; p = 0.028), and with both therapy programs–82, 50 and 62, 34% 
(p < 0.001; p = 0.006). Consequently, a statistically significant relationship has 
been established between the ERCC1-positive variant of the tumor and lower rates 
of 5-year OS and BSV [36].
Nguyen et al. (SFOP) presented the results of a study to determine the prog-
nostic significance of TOP2A protein expression (topoisomerase DNA 2 alfa) and 
the presence of rearrangement of the TOP2A gene in biopsy tumor material in 105 
children with osteosarcoma treated with the SFOP protocol OS94. Patients with a 
primary metastatic osteosarcoma variant accounted for 17%. After neoadjuvant 
chemotherapy, a good histological response was detected in 56 patients (53%) 
and a poor histological response in 49 (47%). Real-time PCR amplification of the 
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TOP2A gene and the TOP2A gene deletion were detected in 21 (21.2%) and 25 
(25.3%) patients. In 53 children (53.5%), rearrangements of the TOP2A gene were 
not detected. A statistically significant relationship was established between the 
presence of the TOP2A gene rearrangement (amplification and deletion) and the 
presence of a good histological response after neoadjuvant polychemotherapy 
(p = 0.004). There was also a tendency to achieve lower rates of 5-year OM and BSV 
in patients whose tumor cells had amplified the TOP2A gene (p = 0.09 and 0.06). 
The expression of the TOR2A protein was determined in 17 patients by immunohis-
tochemistry. Medium (2+) and high (3+) levels of expression were detected in all 
patients; expression was above 30% in 12 of 17 children (70.5%). There is no statis-
tically significant relationship between the expression of the TOR2A protein above 
30% and the presence of amplification or deletion of the TOP2A gene (p > 0.05) 
due to an insufficient number of observations [37].
Xiao et al. presented the results of a study of a personalized approach to the 
prescription of chemotherapy depending on the presence or absence of markers of 
drug resistance in 28 patients with localized osteosarcoma. The average age in the 
patient group was 20.1 g. To determine the sensitivity to chemotherapy, the follow-
ing markers were used: for doxorubicin–expression of TOP2A micro-RNA, muta-
tion of the ABCB1 gene, and mutation of the GSTP1 gene; for cisplatin–expression 
of microcryptal ERCC1, BRCA1, and mutation of genes XRCC1-exon6 and XRCC1-
exon10, and for ifosfamide–mutation of CYP2C9 * 3.
At the same time, a high level of sensitivity to ifosfamide was detected in all 
patients (100%), to cisplatin in 11 out of 28 (39.2%), to doxorubicin in 6 out of 28 
(21.4%); medium and high levels of sensitivity to cisplatin in 17 of 28 (60.7%), 
to doxorubicin in 20 of 28 (71.4%). Chemotherapy, taking into account the sen-
sitivity of the tumor to drugs, was performed in 8 of 28 patients (28.5%). In this 
group, only one relapse of the disease was detected, while in the rest of the 20 
patients, four relapses of the disease were detected: in one case, progression during 
neoadjuvant chemotherapy and in another case, fatal outcome from toxicity of 
therapy. The average duration of observation for groups was not indicated, and no 
statistically significant difference was obtained due to the insufficient number of 
observations [39].
In addition, the study of markers of stem tumor cells CD133 (Prominin 1) and 
Octamer-binding transcription factor 4 (OCT4), as well as the transcription factors 
signal transducer and activator of transcription 3 (STAT3), and myelocytomatosis 
viral oncogene homolog (C-MYC), which determines the invasive and metastatic 
potential of a tumor [45–47].
So in the work of He et al., there was a significant correlation between the 
expression of CD133 in tumor cells and a higher frequency of metastatic lesions, a 
lower median of overall survival. A CD133-positive variant was detected in 46 of 70 
(65.7%) patients, in 6 out of 16 (37.5%) in the group with a localized osteosarcoma 
variant, and in 40 out of 54 (74%) in the group with the primary metastatic osteo-
sarcoma (p = 0.002). The median overall survival rate was statistically significantly 
lower in the group with CD133-positive tumor (p = 0.000). When conducting the 
study “Transwell invasion,” a significantly higher invasive potential of the CD133-
positive variant of the tumor was established (p < 0.05). Real-time PCR established 
a higher level of expression of micro-RNA OCT4 in a CD133-positive variant of the 
tumor (p < 0.05) [41].
Li et al. in an experimental model on cell lines showed that about 80% of cells 
in a CD133-positive variant of the tumor are in the G0/G1 phases of the cell cycle 
(p < 0.01). Also, real-time PCR revealed a significantly higher level of expression 
of the multidrug-resistant gene (MDR1) in the CD133-positive variant of the tumor 
(p < 0.05) [48].
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In the studies presented, He and Li et al., the mechanisms of drug resistance, 
invasion, and metastasis in case of CD133-positive variant of the tumor were 
established.
In the works of Tu et al., the significance of activation of the IL6R/STAT3/p-
STAT3tyr705 mesenchymal stem cell signaling pathway to increase the metastatic 
potential of tumor cells was exemplified by the example of cell lines (Saos 2 and 
U2-OS). The relationship between the increased expression of p-STAT3tyr705 and 
increased expression of the drug resistance markers multidrug resistance protein 
(MRP) and MDR1 has been established. An increase in sensitivity to doxorubicin, 
but not to cisplatin, was also noted with inhibition of this signaling pathway [43, 49].
Han et al. using cell lines (MG63 and SAOS2) as an example showed that an 
increase in C-MYC expression leads to activation of the MEK–ERK signaling 
pathway and an increase in the expression of MMP2 and MMP9, which enhance the 
invasive and metastatic potential of a tumor [50].
Wu et al. investigated the prognostic significance of C-MYC expression in 
biopsy tumor material in 56 children with osteosarcoma who were treated with 
methotrexate, cisplatin, and adriamycin. Expression of the C-MYC protein was 
detected in 48 of 56 (85.7%) patients. A statistically significant relationship was 
established between the presence of C-MYC expression and a decrease in the apop-
totic index (p < 0.05). In addition, in the group of patients with C-MYC-positive 
variant of the tumor and the intensity of expression, at 2+ and 3+, a significantly 
lower 3-year-old OM was established (p < 0.05) [51].
Consequently, in the works of Tu, Han, and Wu et al., the significance of tran-
scription factors in the development of drug resistance, invasion, and metastasis of 
the tumor has been established.
3.3 Theoretical treatment
Innovative therapeutic approaches are used mainly in patients with metastatic 
osteosarcoma, relapse, and refractory course of the disease. Currently, the follow-
ing key areas are distinguished: (1) the use of monoclonal antibody preparations, 
(2) tumor-modifying therapy using nitrogen-containing bisphosphonates, (3) the 
use of chemotherapeutic drugs that affect various cellular signaling pathways (mul-
tikinase inhibitors and mTOR inhibitors), and (4) the use of drugs that promote the 
activation of tumor-associated macrophages.
Rossi et al. presented the results of a study aimed at determining the expression 
of vascular endothelial growth factor (VEGF) in a biopsy tumor substrate and 
in tumor material after neoadvanting chemotherapy (two courses of MAP) in 16 
patients with localized osteosarcoma, who received programmed treatment using 
the SSG XIV protocol. Four levels of expression were evaluated: negative and low–at 
an expression level <25%, medium—at 25–50% (1+), high—at 50–75% (2+), and 
very high—at>75% (3+). Medium and high levels of VEGF expression in biopsy 
tumor material were detected in 11 (6 in medium and 5 in high) out of 16 patients 
(68.7%). After neoadjuvant chemotherapy and the removal of the primary tumor 
site, VEGF expression was established in all samples, and there was an increase in 
expression in samples that were positive in the initial study.
High and very high levels of expression, increased expression after neoadjuvant 
chemotherapy was statistically significantly correlated with the localization of the 
primary tumor lesion in the femur (p = 0.02), with the appearance of local recur-
rence (p = 0.04) and/or early metastatic lesions in the lungs (p = 0.04), with a fatal 
outcome from the refractory course of the disease (p = 0.04).
Therefore, the presence of VEGF expression in the biopsy material and an 
increase in the expression of VEGF after neoadjuvant chemotherapy are factors for 
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poor prognosis of the disease [42]. But this study requires the continuation of the 
fact that it includes a small number of patients.
In addition, Ohba et al. showed in an in vivo experiment using human osteosar-
coma cell lines (TE85 and 143B) the mechanism of autocrine stimulation of tumor 
transformation and proliferation using the example of the VEGF/VEGFR signaling 
pathway. In this study, the expression of VEGF-A and VEGFR micro-RNA was 
evaluated [52].
Currently, little experience has been gained with the use of the drug bevaci-
zumab in children with osteosarcoma.
Bevacizumab (Avastin) is a partially humanized monoclonal antibody to 
VEGF-A, IgG1, which realizes its activity through a second type of immunopatho-
logical reaction (antibody-mediated complement-dependent cytotoxicity and 
antibody-mediated cell-dependent cytotoxicity) [53].
Turner et al. (St. Jude Children’s research hospital) presented preliminary results 
of using bevacizumab in combination with neoadjuvant chemotherapy (two courses 
of IDA) in 27 children with osteosarcoma. The drug was used at a dose of 15 mg/kg. 
There are three introductions for neoadjuvant chemotherapy. A satisfactory toxicity 
profile has been established. The study NCT00667342 continues [54, 55].
Back in 1999, employees of the Memorial Sloan-Kettering Cancer Center 
presented the results of a study assessing the effect of ErbB2 expression (Erb-B2 
receptor tyrosine kinase 2) on the nature of the histological response after neoad-
juvant polychemotherapy and on the rates of OS and BSV. The study included 53 
patients. ErbB2 overexpression was detected in 42% of patients in the entire study 
group, in 50% with metastatic variant and in 76% at the time of detection of relapse 
or refractory course of the disease, and also statistically significantly correlated 
with poor histological response (p = 0.02) and BSV (p = 0.05). The 5-year BSV in 
patients with a localized version of osteosarcoma and ErbB2-positive status was 
47%, with ErbB2-negative status—79% [40].
Conflicting data on the prognostic significance of ErbB2-positive status in 
patients with localized osteosarcoma were obtained.
In 2002, the Japanese Osteosarcoma Group (Japanese Osteosarcoma Group) 
published the results of a study that included 155 patients with localized osteo-
sarcoma from 1984 to 1995. At the same time, 5-year BSV in patients with ErbB2-
positive status was 45%, with ErbB2-negative status—72% [56].
In 2014, the Children Oncology Group (COG) presented completely different 
results of the study, which from 1999 to 2002 included 135 patients with localized 
osteosarcoma. Only 13% of patients showed ErbB2-positive status. The 5-year RR in 
patients with ErbB2-positive status was 73%, and with the ErbB2-negative sta-
tus—72%, the 5-year RR was 59 and 69%, respectively. No statistically significant 
difference in survival was observed [57].
Thus, it was confirmed that ErbB2 can be considered as a potential target for 
targeted therapy in metastatic variant, relapse, and refractory course of the disease.
COG presented the results of a phase 2 clinical trial of the drug Trastuzumab 
(Herceptin) in combination with MAPIE polychemotherapy in 96 patients with 
primary metastatic osteosarcoma. This study was conducted from 2001 to 2005.
Trastuzumab is a partially humanized IgG1κ monoclonal antibody to ErbB2, 
which also realizes its activity through a second type of immunopathological reac-
tion (antibody-mediated complement-dependent cytotoxicity and antibody-medi-
ated cell-dependent cytotoxicity). The drug was administered at a dose of 4 mg/kg 
in the first week, and then 2 mg/kg 1 time per week (34 in total) only in patients in 
whose tumor substrate ErbB2 expression was detected.
Surgical removal of the primary tumor lesion was performed at week 11. 
Adjuvant chemotherapy began at week 13.
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In the group with trastuzumab, a good histological response was detected in 
56% of patients and without trastuzumab, it was 40%, a poor histological response 
of 44–60%, respectively. At the same time, the 3-year OS and BSV in the group of 
patients who received treatment with trastuzumab accounted for 59 and 32%, and 
in the group of patients who received treatment without trastuzumab for 50 and 
32%. Consequently, the use of trastuzumab with polychemotherapy MAPIE led to 
an increase in the frequency of achieving a good histological response, but not to an 
increase in the rates of OS and EFS [58].
Of particular interest is tumor-modifying therapy using nitrogen-containing 
bisphosphonates. Currently, the following mechanisms of action of nitrogen-con-
taining bisphosphonates have been identified, which are represented by the activa-
tion of tumor cell apoptosis by the caspase mechanism (indirectly through protein 
Rb and P53) and without the participation of the caspase mechanism (an increase 
in AIF—apoptosis of the inducing factor); increased expression of TNF-related 
apoptosis-inducing ligand–death receptor 5 (TRAIL-DR5, TRAIL-induced apop-
tosis); reduction of receptor activator of nuclear factor kappa-B ligand (RANKL) 
expression–ligand of nuclear factor activation receptor kB in osteosarcoma cells, 
which leads to suppression of tumor cell proliferation, osteoclast activity, changes in 
the tumor microenvironment, bone resorption, and risk of metastasis; γδT activation 
of cellular cytotoxicity; and tumor activation of associated macrophages [59–62].
In addition, the potentiating effect of nitrogen-containing bisphosphonates on 
cisplatin and adriamycin has been confirmed [63].
Currently, a rather small experience has been gained in using these drugs in 
children with osteosarcoma.
Meyers et al. published the results of a study on the combined use of pami-
dronate with MAP chemotherapy. The study included 40 patients, 32 in the age 
group under 18, 29 with a localized version of osteosarcoma, and 11 with a primary 
metastatic option of osteosarcoma.
In accordance with the program, pamidronate was administered once a 
month at a dose of 2 mg/kg 48–72 h after adriamycin, methotrexate, a total of 12 
administrations.
Surgical removal of the primary tumor lesion was performed at week 11. 
Adjuvant chemotherapy began at week 13. Removal of metastatic foci was carried 
out individually at the stage of adjuvant therapy.
The frequency of achieving a good and poor histological response is not indi-
cated. However, relatively high rates of 5-year OS and EFS were obtained: 93 and 
72% in patients with localized osteosarcoma and 64 and 45% in patients with 
metastatic osteosarcoma [26].
COG presented the results of the pilot protocol AOST06P1 aimed at studying the 
combined use of zoledronic acid with MAPIE polychemotherapy in children with 
the primary metastatic osteosarcoma. This study included 24 patients. Zoledronic 
acid was administered at a dose of 1.2–3.5 mg/m2 in each course of chemotherapy.
The maximum tolerated dose of zoledronic acid was established, which was 
2.3 mg/m2. Indicators of a 2-year OV and EFS were 60 and 32%, respectively [63].
Piperno-Neumann et al. presented the results of a phase 3 randomized study OS 
2006, the purpose of which was to identify the potentiating effect of zoledronic acid 
when used together with polychemotherapy MIE and MAP.
The study included 217 children, 107 in the control group, and 110 in the group 
with zoledronic acid. Groups of patients were statistically significantly comparable 
by sex, age, foci of primary and metastatic lesions, and histological variant of the 
tumor.
Zoledronic acid was administered at a dose of 0.05 mg/kg (maximum dose of 
4 mg) with each course of chemotherapy (IE and AP).
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Neoadjuvant chemotherapy consisted of two courses of IE (ifosfamide (I) 12 g/m2, 
etoposide 300 mg/m2) and seven administrations of high-dose methotrexate ((M) 
12 g/m2). Surgical removal of the primary tumor lesion was performed at week 
14. Adjuvant chemotherapy included two courses of MIE in the group with a good 
histological response and five courses of MAP in the group with a poor histological 
response. A good histological response after neoadjuvant polychemotherapy was 
achieved in 73% of patients. However, there was no statistically significant differ-
ence in achieving a good histological response, in terms of OS and BSV in groups 
of patients who received programmed treatment with or without zoledronic acid. 
The number of events in the group with zoledronic acid was 42% (47/110) and 
in the group without zoledronic acid was 31% (34/107). Consequently, this study 
shows the high effectiveness of chemotherapy courses with IE in combination with 
methotrexate in the neoadjuvant regimen. The presence of the potentiating effect of 
zoledronic acid has not been proven [64].
In the treatment of refractory forms of osteosarcoma, drugs are also used that 
affect various cellular signaling pathways. Understanding the mechanisms of tumor 
activation opens up the possibility of using multikinase and mammalian target of 
rapamycin complex (mTOR) inhibitors.
Takagi and Peng et al. in an in vitro experiment on cell lines (SaOS2, MG63, 
HOS), pathogenetic mechanisms of cytokine-induced tumor transformation and 
proliferation were shown through the activation of VEGF/VEGFR/PI3K (phospha-
tidylinositol-4,5-bisphosphate 3-kinase)/AKT (protein kinase B) and the platelet-
derived growth factor receptor (PDGFR)/PI3K/AKT signaling pathways [65, 66]. 
The most studied drugs from this group are currently sorafenib (nexavar) and 
everolimus (afinitor) [67]. Sorafenib is a nonselective multikinase inhibitor that 
inhibits the activity of various cellular signaling pathways, in particular VEGFR1, 
VEGFR2, PDGFRα, and PDGFRβ, while everolimus is an mTOR inhibitor [68].
Ymera et al. of the Italian Sarcoma Group published the results of a preclinical 
study (in vitro and in vivo), which noted the mutually potentiating antitumor 
effect of everolimus and sorafenib on osteosarcoma cell lines (KHOS, MNNG-HOS, 
and U2OS). The effect of everolimus and sorafenib on mTORC1/mTORC2 is mani-
fested in a decrease in the expression of mTORC1 and an increase in the expression 
of mTORC2, which provides proapoptotic and antiproliferative effects. With the 
combined use of everolimus and sorafenib, there is a decrease in the expression of 
both mTORC1 and mTORC2 [69].
From 2008 to 2009, Grignani et al. of the Italian Sarcoma Group conducted a 
second phase of clinical trials of the drug sorafenib in patients with relapse and 
refractory osteosarcoma. The study included 35 patients with osteosarcoma in the 
age group over 14 years. Partial response was achieved in 5 (14%) patients and 
stabilization of the disease in 12 (34%) patients. The overall response rate was 48%. 
At the same time, 4-month progression-free survival was 45% (15 out of 35) [70].
From 2011 to 2013, Grignani et al. conducted a second phase of clinical trials of 
a combination of drugs of everolimus and sorafenib in patients with relapse and 
refractory osteosarcoma after performing standard polychemotherapy MAP (study 
NCT01804374). The study included 38 patients over the age of 18 years. Everolimus 
was administered in a dose of 5 mg once a day and sorafenib 400 mg two times a 
day. The duration of chemotherapy was 28 days. Partial response was achieved in 
4 (10%) patients and stabilization of the disease in 20 (53%) patients. The overall 
response rate is 63%. This figure is 15% more than in the study, where sorafenib 
was used in monomode. A 4-month progression-free survival was 58% and for 
6-month, it was 45% (17 out of 38) [71].
Thus, taking into account the data of studies in 2008 (application of sorafenib in 
mono mode) and 2011 (using a combination of sorafenib with everolimus), it can 
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be said that the combination of sorafenib with everolimus leads to an increase in the 
overall response rate and an increase in survival rate without disease progression 
within 6 months. However, by the year, this difference disappears.
At ASCO 2016, preliminary results were presented in a pilot study of the use of 
everolimus/sorafenib in children with relapse and refractory osteosarcoma, which 
was carried out at the Institute of Pediatric Oncology and Hematology N.N. Blokhin 
Medical Research Center of Oncology from 2013 to 2016. This protocol included 
14 patients. The first line of therapy is represented by the program “Osteosarcoma 
2006” in seven patients and “Osteosarcoma 2014” in seven patients. All patients 
underwent therapy, which included doxorubicin, cisplatin, high-dose methotrex-
ate, high-dose ifosfamide, and gemcitabine and docetaxel.
The number of courses of therapy for everolimus/sorafenib ranged from 2 to 18. 
The toxicity of therapy was erythema cutaneous in all patients (100%), palmar and 
plantar syndrome in 1 (7%), and mucositis 1–2 in 4 (28.5%). Hematologic toxicity 
did not exceed 1–2 degree in all patients. A transient increase in transaminases up to 
five norms in all patients (100%) was also noted.
Partial response to treatment was achieved in 5 of 14 (35.7%) patients and sta-
bilization of the disease in 9 (64.3%). The overall response rate was 100%. Survival 
without disease progression for more than 6 months was detected in 6 out of 14 
(43%) patients. The mean follow-up was 7 ± 1.2 months. The maximum period 
without progression of the disease is 18.4 months.
The findings suggest that everolimus/sorafenib combination resulted in a partial 
response in 35.7% of cases with a satisfactory toxicity profile [72].
Compared to international data (Italian sarcoma group) in the presented study, 
the achievement of a partial response, stabilization of the disease, and the overall 
response rate were significantly higher.
Currently, a number of studies aimed at studying the role of tumor-associated 
macrophages. Activation of tumor-associated macrophages can be achieved 
through the use of preparations of liposomal tripeptides (mifamurtide) and inter-
feron preparations (interferon alpha-2A).
Meyers et al. presented the results of the randomized study CCG 7921/POG 
9351, which was conducted from 1993 to 1997. The study included 662 patients with 
a localized version of osteosarcoma.
A feature of line A therapy was the use of two courses of neoadjuvant chemo-
therapy for MAP, and in line B therapy, two courses of neoadjuvant chemotherapy 
MAi, alternating courses of MAR and MAi at the stage of adjuvant chemotherapy, 
was used. Surgical removal of the primary tumor lesion was performed at week 10. 
Mifamurtide (MTP) was administered at a dose of 2 mg/m2 two times a week for 
12 weeks, and then once a week for 24 weeks in accordance with randomization.
The mechanism of action of mythamurtide (MTP) is to activate monocytes/
macrophages with antitumor activity, which is realized by binding to specific recep-
tors toll-like receptor 4 (TLR4) and nucleotide-binding oligomerization domain 
2 receptor (NOD2), followed by altering the activity of cellular signal pathways 
(ERK1/2—extracellular-signal regulated kinase 1/2), NF-kB—nuclear factor kappa-
B, and AP1—adapter protein 1 [73].
After removal of the primary tumor focus, a good histological response in group 
A was achieved in 42% of patients and in group B in 48%, and a poor histologi-
cal response in group A was 58% and in group B was 52%. At the same time, the 
6-year-old RH was 74%, without the use of MTP was 70% and with the MTP was 
78%; BSV was 64%, without the use of MTR was 61% and with MTP was 67%. In 
group A: OS without the use of MTR was 71% and with MTR was 75%; BSV without 
MTR was 64% and with MTR was 63%. In group B: OS without the use of MTR was 
71% and with MTR was 75%; BSV without MTR was 64% and with MTR was 63%. 
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The addition of MTP to polychemotherapy led to a statistically significant increase 
in the 6-year OS from 70 to 78% (p = 0.03), and there was also a tendency to an 
increase in BSV, mainly in group B (p = 0.08) [25].
Kubo et al. published the results of a pilot study that determined the prognostic 
significance of the expression level of interferon α/β receptors in 40 patients with 
localized osteosarcoma who received treatment according to the NECO95J program. 
Expression of interferon α/β receptors was detected in 45% of patients. When 
conducting multivariate statistical analysis, a significant association was observed 
between the expression of interferon α/β receptors and 5-year-old OM and survival 
free of metastatic lesions (VSMP). The 5-year OM, in the presence of expression 
of the α/β interferon receptor in the tumor substrate, was 81%, with no expression, 
47% (p = 0.043), and in the 5-year HSMP, it was 75 and 41% (p = 0.023). This 
study confirms the possibility of using interferon preparations in the treatment of 
osteosarcoma in patients with overexpression of α/β interferon receptors [74].
Bielack et al. presented the results of the EURAMOS1 study in patients with a 
good histological response after neoadjuvant MAP chemotherapy. In the age group 
up to 30 years, the MAP line of therapy was carried out to 359 patients, the MAP 
INF line α–2b—to 357 patients, in the age group up to 20 years—333 (92.7%) and 
332 (92.9%) patients. Groups of patients are statistically significantly comparable 
by sex, age, localization of the primary tumor lesion, the presence of metastatic 
lesions, and the histological variant of the tumor.
In accordance with the program, pegylated INF–α–2b was administered at a dose 
of 0.5 mg/kg (at a maximum dose of 50 mg) once a week for 4 weeks, and then 
1 mg/kg (at a maximum dose of 100 mg) 1 time per week (from 30 to 104 weeks of 
programmed treatment).
In a group of 630 patients with a localized version of osteosarcoma, 135 events 
were detected: 72 in patients who received the MAP therapy line and 63 in patients 
who received the MAP INF therapy line–2b. At the same time, the 3-year EFS was 
77 and 80%, respectively. Therefore, the use of INF–α–2b as maintenance therapy 
after MAP in patients with a good histological response did not lead to an increase 
in EFS [75].
The data set out in paragraph 3 are summarized in Table 3.
4. Conclusion
Thus, the results of treatment of children with primary metastatic osteo-
sarcoma, relapse, and refractory course of the disease remain unsatisfactory. 
Molecular biological factors that determine sensitivity to chemotherapy, invasive, 
Authors Agents
Ferrari S. Ifosfamide, adriamycin, cisplatin
Le Deley M.C. Methotrexate, adriamycin, ifosfamide, etoposide
Cui Q. Cisplatin
Pitano-Garcia A. Doxorubicin, cisplatin
Wu X. Methotrexate, cisplatin, adriamycin
Ohba T. Bevacizumab (Avastin)
Children Oncology Group Trastuzumab
Table 3. 
Trials/authors and agents.
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and metastatic potential of the tumor, as well as the prognosis of the disease, among 
which special attention is deserved are as follows: expression of MGMT protein, 
methylation of the promoter part of the MGMT gene, expression of ERCC1 pro-
teins, VEGF, CD133, p-STAT3tyr705, C-MYC, expression of RFC1 micro-RNA, and 
the presence of rearrangement of the TOR2A gene. It is important to note that there 
was no comprehensive assessment of the value of these markers for the histologi-
cal response to neoadjuvant chemotherapy and survival rates in patients with 
osteosarcoma.
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